Literature DB >> 10760801

Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR.

G Tosi1, R Meazza, A De Lerma Barbaro, A D'Agostino, S Mazza, G Corradin, A Albini, D M Noonan, S Ferrini, R S Accolla.   

Abstract

The use of newly generated murine monoclonal antibodies directed against distinct epitopes of a functionally active, chemically synthesized HIV-1 Tat protein has permitted the identification of several molecular forms including monomers, dimers and trimers. Dimers and trimers are particularly stable and resistant to strong reducing conditions. Through epitope mapping it has been possible to demonstrate that the major immunodominant epitope is contained within the basic region of the Tat protein and is lost after oligomerization of the molecule. In contrast, N-terminal, C-terminal and conformation-dependent epitopes are still accessible to mAb specific recognition after Tat oligomerization. Moreover, by using a quantitative HIV-LTR transactivation assay depending upon exogenous Tat, we could extrapolate the amount of functional Tat produced by cell lines stably transfected with the viral transactivator. More importantly, we could show that only the monomeric form of exogenous Tat is the relevant functional form acting in cells harbouring the HIV-1 LTR promoter.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760801     DOI: 10.1002/(SICI)1521-4141(200004)30:4<1120::AID-IMMU1120>3.0.CO;2-4

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Assembly of multiple CotC forms into the Bacillus subtilis spore coat.

Authors:  Rachele Isticato; Giovanni Esposito; Rita Zilhão; Sofia Nolasco; Giuseppina Cangiano; Maurilio De Felice; Adriano O Henriques; Ezio Ricca
Journal:  J Bacteriol       Date:  2004-02       Impact factor: 3.490

2.  Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.

Authors:  Emmanuel Moreau; Johan Hoebeke; Daniel Zagury; Sylviane Muller; Claude Desgranges
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  A Stronger Transcription Regulatory Circuit of HIV-1C Drives the Rapid Establishment of Latency with Implications for the Direct Involvement of Tat.

Authors:  Sutanuka Chakraborty; Manisha Kabi; Udaykumar Ranga
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

4.  Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons.

Authors:  Sylvia Fitting; Ruqiang Xu; Cecilia Bull; Shreya K Buch; Nazira El-Hage; Avindra Nath; Pamela E Knapp; Kurt F Hauser
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

5.  Endolysosome iron restricts Tat-mediated HIV-1 LTR transactivation by increasing HIV-1 Tat oligomerization and β-catenin expression.

Authors:  Nabab Khan; Peter W Halcrow; Leo K Lakpa; Mohd Rehan; Xuesong Chen; Jonathan D Geiger
Journal:  J Neurovirol       Date:  2021-09-22       Impact factor: 2.643

6.  Diametrically opposed effects of hypoxia and oxidative stress on two viral transactivators.

Authors:  Amber T Washington; Gyanendra Singh; Ashok Aiyar
Journal:  Virol J       Date:  2010-05-10       Impact factor: 4.099

7.  An HIV feedback resistor: auto-regulatory circuit deactivator and noise buffer.

Authors:  Leor S Weinberger; Thomas Shenk
Journal:  PLoS Biol       Date:  2007-01       Impact factor: 8.029

8.  Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein.

Authors:  Nagadenahalli Byrareddy Siddappa; Mohanram Venkatramanan; Prasanna Venkatesh; Mohanbabu Vijayamma Janki; Narayana Jayasuryan; Anita Desai; Vasanthapuram Ravi; Udaykumar Ranga
Journal:  Retrovirology       Date:  2006-08-18       Impact factor: 4.602

9.  The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.

Authors:  Greta Forlani; Filippo Turrini; Silvia Ghezzi; Alessandra Tedeschi; Guido Poli; Roberto S Accolla; Giovanna Tosi
Journal:  J Transl Med       Date:  2016-04-18       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.